{"id":1600,"date":"2007-12-15T07:55:53","date_gmt":"2007-12-15T11:55:53","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=1600"},"modified":"2007-12-15T07:59:22","modified_gmt":"2007-12-15T11:59:22","slug":"revision-sindrome-de-hipersensibilidad-a-la-dapsona-shd","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/1600","title":{"rendered":"Revisi\u00f3n: Sindrome de Hipersensibilidad a la Dapsona (shd)"},"content":{"rendered":"<p><strong>Autor: J Qui\u00f1onez-Chah\u00edn.<br \/> Residente de Segundo  a\u00f1o Hospital Vargas. Instituto de Biomedicina<\/strong><\/p>\n<ul>\n<li>Reacciones adversas a f\u00e1rmacos frecuentes: 2 y 3% de los ptes. <\/li>\n<li>1\/1.000 ptes. presenta una reacci\u00f3n cut\u00e1nea severa. <\/li>\n<li>La incidencia del (SHD) es menos com\u00fan, de 1\/ 1.000 a 10.000 <\/li>\n<li>Las reacciones a drogas son enfermedades autolimitadas. <\/li>\n<li>Tratamiento sintom\u00e1tico. <\/li>\n<li>Tasa de mortalidad del SHD es aprox. 10%. <\/li>\n<li>Asociado a hepatitis puede aumentar entre 18 y 38%, por lo que es importante hacer el diagn\u00f3stico en su etapa inicial.&nbsp; <\/li>\n<\/ul>\n<p><!--more--><br \/> Descargue esta revisi\u00f3n completa aqu\u00ed:<\/p>\n<table cellspacing=\"0\" cellpadding=\"0\">\n<tr>\n<td><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/mail.google.com\/mail\/images\/pdf.gif\" alt=\"pdf\" width=\"16\" height=\"16\" \/><\/td>\n<td width=\"7\">&nbsp;<\/td>\n<td><strong>cartelera del residente.ppt<\/strong><br \/> 63K    <a href=\"http:\/\/piel-l.org\/blog\/wp-content\/uploads\/2007\/12\/182\/shd.pdf\" target=\"_blank\">Descargar documento<\/a> <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Autor: J Qui\u00f1onez-Chah\u00edn. Residente de Segundo a\u00f1o Hospital Vargas. Instituto de Biomedicina Reacciones adversas a f\u00e1rmacos frecuentes: 2 y 3% de los ptes. 1\/1.000 ptes. presenta una reacci\u00f3n cut\u00e1nea severa. La incidencia del (SHD) es menos com\u00fan, de 1\/ 1.000 a 10.000 Las reacciones a drogas son enfermedades autolimitadas. Tratamiento sintom\u00e1tico. Tasa de mortalidad del &hellip;<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31],"tags":[],"class_list":["post-1600","post","type-post","status-publish","format-standard","","category-fichas-bibliograficas"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/1600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=1600"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/1600\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=1600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=1600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=1600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}